| Ident. | Authors (with country if any) | Title |
|---|
| 000115 (2011) |
James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada] | The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease |
| 000117 (2011) |
Vibeke Guldbrand Rasmussen [Danemark] ; Karen Stergaard [Danemark] ; Erik Dupont [Danemark] ; Steen Hvitfeldt Poulsen [Danemark] | The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists |
| 000230 (2011) |
Lucia Frau [Italie] ; Franco Borsini [Italie] ; Jadwiga Wardas [Pologne] ; Amit S. Khairnar [Italie] ; Nicoletta Schintu [Italie] ; Micaela Morelli [Italie] | Neuroprotective and anti‐inflammatory effects of the adenosine A2A receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease |
| 000722 (2010) |
M. Soilu-H Nninen ; E. Broberg ; M. Röytt ; P. Mattila ; J. Rinne [Finlande] ; V. Hukkanen [Finlande] | Expression of LIF and LIF receptor beta in Alzheimer’s and Parkinson’s diseases |
| 000724 (2010) |
Marta G. Vu Ckovi [États-Unis] ; Quanzheng Li [États-Unis] ; Beth Fisher [États-Unis] ; Angelo Nacca [États-Unis] ; Richard M. Leahy [États-Unis] ; John P. Walsh [États-Unis] ; Jogesh Mukherjee [États-Unis] ; Celia Williams [États-Unis] ; Michael W. Jakowec [États-Unis] ; Giselle M. Petzinger [États-Unis] | Exercise elevates dopamine D2 receptor in a mouse model of Parkinson's disease: In vivo imaging with [18F]fallypride |
| 000912 (2009) |
David A. Price [États-Unis] ; Alex A. Martinez [États-Unis] ; Alexandre Seillier [États-Unis] ; Wouter Koek [États-Unis] ; Yolanda Acosta [États-Unis] ; Elizabeth Fernandez [États-Unis] ; Randy Strong [États-Unis] ; Beat Lutz [Allemagne] ; Giovanni Marsicano [France] ; James L. Roberts [États-Unis] ; Andrea Giuffrida [États-Unis] | WIN55,212‐2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mouse model of Parkinson’s disease |
| 000926 (2009) |
Chen [États-Unis] ; Swope [États-Unis] ; Dashtipour [États-Unis] ; Lyons [États-Unis] | Transdermal Rotigotine: A Clinically Innovative Dopamine‐Receptor Agonist for the Management of Parkinson's Disease |
| 000A14 (2009) |
Hiroki Takeuchi [Japon] ; Takashi Yanagida [Japon] ; Masatoshi Inden [Japon] ; Kazuyuki Takata [Japon] ; Yoshihisa Kitamura [Japon] ; Kentaro Yamakawa [Japon] ; Hideyuki Sawada [Japon] ; Yasuhiko Izumi [Japon] ; Noriyuki Yamamoto [Japon] ; Takeshi Kihara [Japon] ; Kengo Uemura [Japon] ; Haruhisa Inoue [Japon] ; Takashi Taniguchi [Japon] ; Akinori Akaike [Japon] ; Ryosuke Takahashi [Japon] ; Shun Shimohama [Japon] | Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone‐induced Parkinson's disease models |
| 000B10 (2009) |
Rogan B. Tinsley [Australie] ; Chris R. Bye [Australie] ; Clare L. Parish [Australie] ; Angela Tziotis-Vais [Australie] ; Sonia George [Australie] ; Janetta G. Culvenor [Australie] ; Qiao-Xin Li [Australie] ; Colin L. Masters [Australie] ; David I. Finkelstein [Australie] ; Malcolm K. Horne [Australie] | Dopamine D2 receptor knockout mice develop features of Parkinson disease |
| 000D52 (2008) |
Chun-Hung Lin ; Jui-Yen Huang [Taïwan] ; Cheng-Hsin Ching ; Jih-Ing Chuang [Taïwan] | Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone‐induced parkinsonian rats |
| 000E15 (2008) |
Masaki Wakamatsu [Japon] ; Shingo Iwata [Japon] ; Takeo Funakoshi [Japon] ; Makoto Yoshimoto [Japon] | Dopamine receptor agonists reverse behavioral abnormalities of α‐synuclein transgenic mouse, a new model of Parkinson's disease |
| 000E73 (2008) |
Peter A. Lewitt [États-Unis] ; M. Guttman [Canada] ; James W. Tetrud [États-Unis] ; Paul J. Tuite [États-Unis] ; Akihisa Mori [Japon] ; Philip Chaikin [États-Unis] ; Neil M. Sussman [États-Unis] | Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005) |
| 000F99 (2007) |
Chiung-Mei Chen [Taïwan] ; I-Cheng Chen [Taïwan] ; Kuo-Hsuan Chang [Taïwan] ; Yi-Chun Chen [Taïwan] ; Rong-Kuo Lyu [Taïwan] ; Yen-Tzu Liu [Taïwan] ; Fen-Ju Hu [Taïwan] ; Chih-Ying Chao [Taïwan] ; Guey-Jen Lee-Chen [Taïwan] ; Yih-Ru Wu [Taïwan] | Nuclear receptor NR4A2 IVS6 +18insG and brain derived neurotrophic factor (BDNF) V66M polymorphisms and risk of Taiwanese parkinson's disease |
| 001124 (2007) |
Annalisa Pinna [Italie] ; Silvia Pontis [Italie] ; Franco Borsini [Italie] ; Micaela Morelli [Italie] | Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6‐hydroxydopamine rat model of Parkinson's disease |
| 001223 (2006) |
Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bédard [Canada] ; Thérèse Di Paolo [Canada] | Prevention of levodopa‐induced dyskinesias by a selective NR1A/2B N‐methyl‐D‐aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin |
| 001232 (2006) |
Monzy Thomas ; Jennifer M. Harrell [États-Unis] ; Yoshihiro Morishima [États-Unis] ; Hwei-Ming Peng [États-Unis] ; William B. Pratt [États-Unis] ; Andrew P. Lieberman [États-Unis] | Pharmacologic and genetic inhibition of hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction |
| 001476 (2005) |
Anna H Kansson [Suède] ; Lars Westberg [Suède] ; Staffan Nilsson [Suède] ; Silvia Buervenich [Suède] ; Andrea Carmine [Suède] ; Björn Holmberg [Suède] ; Olof Sydow [Suède] ; Lars Olson [Suède] ; Bo Johnels [Suède] ; Elias Eriksson [Suède] ; Hans Nissbrandt [Suède] | Interaction of polymorphisms in the genes encoding interleukin‐6 and estrogen receptor beta on the susceptibility to Parkinson's disease |
| 001506 (2005) |
Fang Du [République populaire de Chine] ; Rui Li [République populaire de Chine] ; Yuangui Huang [République populaire de Chine] ; Xuping Li [République populaire de Chine] ; Weidong Le [République populaire de Chine] | Dopamine D3 receptor‐preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons |
| 001836 (2002) |
C. Parkinson ; W. M. Drake [Royaume-Uni] ; G. Wieringa ; A. P. Yates [Royaume-Uni] ; G. M. Besser [Royaume-Uni] ; P. J. Trainer | Serum lipoprotein changes following IGF‐I normalization using a growth hormone receptor antagonist in acromegaly |
| 001923 (2002) |
Yun J. Kim [Canada] ; Masanori Ichise [Canada] ; James R. Ballinger [Canada] ; Douglas Vines [Canada] ; Sean S. Erami [Canada] ; Tatsuro Tatschida [Canada] ; Anthony E. Lang [Canada] | Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP |
| 001A17 (2001) |
Diana Frechilla [Espagne] ; Almudena Cobreros [Espagne] ; Laura Saldise [Espagne] ; Rosario Moratalla [Espagne] ; Ricardo Insausti [Espagne] ; M-Rosario Luquin [Espagne] ; Joaquín Del Río [Espagne] | Serotonin 5‐HT1A receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys |
